❗ IMPORTANT NOTICE FOR JOB SEEKERS ❗ It has come to our attention that fraudulent activity has taken place in reference to Structure employees contacting job-seeking candidates regarding potential job opportunities with our firm, and sending offer letters on behalf of our organization. These fraudulent messages sometimes include a request for payment and confidential personal information. Please note that Structure’s recruiting process does not include asking candidates for payments or other highly confidential financial information. If you are contacted or approached by anyone who is pretending to be employed with Structure in this manner, please report them immediately by sending a message via LinkedIn or contacting us at https://lnkd.in/euCsybM3. We take this matter very seriously and are taking all appropriate measures to address this. Please find our open roles for consideration and follow the application process on our careers page here: https://lnkd.in/e7rmR-RX
Structure Therapeutics
Biotechnology Research
South San Francisco, California 5,014 followers
Creating innovative, life-changing medicines for patients using advanced computational and structure-based technology.
About us
Structure Therapeutics creates life-changing medicines for patients using advanced computational and structure-based technology. Our platform combines the latest advancements in computational chemistry, visualization of molecular interactions, and data integration to design orally available, superior medicines that overcome current limitations in biologic and peptide drugs. We are advancing our clinical-stage pipeline of differentiated, efficacious and safe treatments focused on chronic diseases with high unmet need, including cardiovascular, metabolic and pulmonary conditions. At Structure, our team’s deep experience with complex biological targets and mechanisms, structure-based drug design, and global drug discovery and development enables our bold vision: to design and develop world-class medicines with tremendous patient impact and broad commercial opportunity.
- Website
-
https://structuretx.com/
External link for Structure Therapeutics
- Industry
- Biotechnology Research
- Company size
- 51-200 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2017
- Specialties
- Metabolic Diseases, Cardiovascular Diseases, Pulmonary, Diabetes, Computational Chemistry, and Obesity
Locations
-
Primary
601 Gateway Blvd
Suite 900
South San Francisco, California 94080, US
-
11F, Changtai Plaza Building A, Lane 2889 Jinke Road
Shanghai, China 201203, CN
Employees at Structure Therapeutics
Updates
-
On #NationalInternDay, we’re extending our gratitude to the young, bright interns who have joined us at our San Francisco and Shanghai locations. Over the past couple months, this group has brought a new energy to our team while gaining real-world experience within the #biotech field. It’s been a pleasure working alongside them and sharing our love for the mission we have and the work we do.
-
-
For those that face Type 2 #diabetes, there can often be a heavy amount of misconceptions and stereotypes. We are supporting our partners at Beyond Type 2 this week as they fight to end the stigma around Type 2, creating a more honest and understanding narrative. Learn more below.
This week with Beyond Type 2, we’re talking ALL about the stigmas that people living with diabetes face every day—online, at work, at school, at home and even in the doctor’s office. 👉 ALL people with diabetes are stigmatized, but a lot of those stigmas and misconceptions are framed around type 2 diabetes. 👉 We know we are stronger together. We know stigmas, stereotypes, and not receiving proper care and support based on diabetes type has driven division among people who live with different types of diabetes. Because of those same stigmas, stereotypes, and inadequate care, our collective voices raised together—across all diabetes types—is a vitally needed shift. Flip through these images to learn more. Let’s stop the stigma together. 🛑
-
-
-
-
-
3
-
-
We had a wonderful time hosting our families for the day at our office and lab space in Shanghai. During our family day, we toured our facilities and showed our loved ones what a day in the #biotech world looks like. We believe in the importance of #STEM education, and our children were especially inspired by the roles scientists play in making a difference for patients living with disease. Following the office tour, we enjoyed a nice dinner with great food and even greater company.
-
-
-
-
-
2
-
-
Chronic diseases, including obesity, are rapidly increasing worldwide, escalating the demand for life-changing medicines. At Structure, we are determined to address these devastating #obesity figures with innovative, #smallmolecule medicines without the inherent limitations of peptides and biologics. Oral small molecule drugs can offer improved patient experience and broad access. Learn more about our platform here: https://lnkd.in/eHpMkXRm
-
Our internal global recognition program, Structure Impact, recognizes our team members' exceptional work and celebrates those who embody our core values day in and day out. We're excited to introduce you to our Structure Salute recipients each quarter and share their above and beyond employee contributions.
-
Our full team came together for an inspiring company retreat giving us the opportunity to align our mission for the future. During three action-packed days with numerous breakout sessions and activities, we fostered stronger connections, reaffirmed our dedication to our core values and shared insights from our individual teams to help further advance our patient-focused vision of making medicines more accessible to all. See below for a highlight reel of some of the trip's best moments.
-
That's a wrap for #ADA2024! Our team enjoyed showcasing data from our Phase 1b/2a study of GSBR-1290, a #smallmolecule #GLP1 receptor agonist in development for people living with #obesity and #type2diabetes. Following our time at the event, we're feeling inspired by the work being done in our industry for patients and look forward to sharing more about our innovative science.
-
-
In commemoration of the three-day Chinese #DragonBoatFestival celebration, the team at our Shanghai office hosted a series of activities true to Chinese tradition and culture. From knitting and making sachets to creating leaf fans, we enjoyed crafting while snacking on an assortment of dumplings and rice cakes.
-
-
Our CEO Raymond Stevens recently spoke with CNBC Fast Money's Melissa Lee to discuss our progress with our #GLP1 receptor agonist drug, GSBR-1290, and its potential to become a best-in-class oral treatment for people living with #obesity, and the scalability of #smallmolecule drugs. Watch the full clip here: https://lnkd.in/eiuBxUz7